Serum Adiponectin Level and Clinical, Metabolic, and Hormonal Markers in Patients with Polycystic Ovary Syndrome

Yunus Yildiz, M.D., Gülınur Ozaksit, M.D., Bekir Serdar Unlu, M.D.*, Emre Ozgu, M.D., Hasan Energın, M.D., Metin Kaba, M.D., Mustafa Ugur, M.D.

Department of Obstetrics and Gynecology, Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey

Abstract

Background: To investigate the relationship between adiponectin, metabolic and hormonal parameters, and insulin resistance in patients with non-treated polycystic ovary syndrome.

Materials and Methods: In this cross-sectional observational study, 81 patients admitted to out-patient clinic with complaints of menstrual irregularity, hirsutism and obesity were enrolled. Serum adiponectin, biochemical and hormonal parameters, and 75 gram oral glucose tolerance test (OGTT) were measured. Spearman’s correlation coefficient was used for statistical analysis.

Results: We observed inverse correlations between serum adiponectin level and body mass index, homeostasis model assessment insulin-resistance score, insulin level, fasting glucose level, and prolactin level (p=0.001, p=0.02, p=0.04, p=0.02, and p=0.005, respectively). No significant correlations were found between serum adiponectin level and age, height, weight, Ferriman-Gallwey score, 2 hours OGTT test value and free testosterone level (p=0.3, p=0.6, p=0.2, p=0.8, p=0.9, and p=0.01, respectively).

Conclusion: The present study demonstrated that in polycystic ovary syndrome patients, when serum adiponectin level decreased, degree of insulin resistance increased. Our findings indicate that serum adiponectin level is likely to be an adequate marker for determination of the degree of insulin resistance, and may be a predictor of diseases, such as type 2 diabetes mellitus (T2DM) and metabolic syndrome, which develop on the basis of insulin resistance.

Keywords: Adiponectin, Insulin Resistance, Polycystic Ovary Syndrome

Introduction

Polycystic Ovary Syndrome (PCOS), as a heterogeneous disease, is characterized by menstrual dysfunction, clinical or metabolic hyperandrogenism, and in some patients, and sometimes polycystic appearance in any or both ovaries in radiological imaging (1, 2). Insulin resistance and hyperinsulinemia are the most common characteristic findings in patients with PCOS (3). In recent studies, they have reported an increased insulin response against serum glucose level and an insulin resistance in 26-60% of obese and non-obese patients with PCOS (4). However, the degree of insulin resistance has been shown to be higher in obese PCOS patients than in non-obese PCOS patients (5).

Adiponectin is one of adipocytokines secreted from visceral adipose tissue, and is only secret-
ed by mature adipocytes. The serum concentration of adiponectin decreases in obese patients, opposite to other adipocytokines, even though, it is only secreted by adipose tissue. Adipose tissue takes place as the central organ of systemic insulin sensitivity by synthesis and secretion of adiponectin (6).

There are many studies on adiponectin in patients with PCOS. However, little is known about the biology of adiponectin and its role in further systemic metabolic problems (2).

Adiponectin was correlated with insulin sensitivity (7) and the low levels of adiponectin are associated with increased risk of type 2 diabetes (8).

In recent studies, serum adiponectin level progressively decreased in patients according to the severity of obesity, insulin resistance, diabetes mellitus and cardiovascular diseases. Reduced serum level of adiponectin was determined before onset of symptoms and the beginning of clinical findings. Therefore, low serum adiponectin level may be a predictive factor for type 2 diabetes mellitus (T2DM) and other cardiovascular diseases (9).

In our study, we have examined the degree of insulin resistance in patients with PCOS. Our most important aim was to evaluate the role of insulin resistance in PCOS patients and to determine the predictive capacity of adiponectin for further metabolic abnormalities.

Materials and Methods

Subject and study design

This cross-sectional observational study was performed with a total of 81 patients. The participants were selected via simple random sampling method among total of five hundred PCOS patients who were admitted to Adolescent Outpatient Clinics of the Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey, with menstrual irregularity, hirsutism and obesity between August 2010 and August 2011. Ethics approval was obtained from our institutional review board. Informed written consent was obtained from all participants. The participants were selected according to the 2006 Androgen Excess Society (AES) criteria for PCOS patients, so inclusion criteria were as follows: i. no PCOS treatment for the last 3 months, ii. normal thyroid function, iii. normal prolactin serum levels, iv. the absence of other diseases causing ovulatory dysfunction, and v. abnormal androgen metabolism. Demographic features of patients, like weight and height, as well as clinical criteria, including hirsutism (Ferriman-Gallway >8), acne or male pattern alopecia, were recorded. The following tests were performed for all participants who were instructed to follow a 12 hours fasting and a 24 hours avoidance of excessive exercise and alcohol: i. biochemical measurements including serum fasting insulin levels and fasting glucose levels using chemiluminescence detection method, ii. hormonal measurements including free testosterone using radioimmunassay method, serum prolactin levels (PRL), and 17-hydroxy progesterone (17-OH PROG), and iii. 75-gram oral glucose tolerance test (OGTT). Many methods exist for the measurement the degree of insulin resistance. Although the best method is the euglysemic clamping test, due to technical difficulties, we preferred to use the homeostasis model assessment insulin-resistance (HOMA-IR) score, fasting plasma glucose level, fasting plasma insulin level and 24 hours OGTT test value. Height was measured by stadiometer and weight was measured in our outpatient clinic. Body mass index (BMI) was calculated using the following formula: weight (kg)/height (meter) squared. Plasma adiponectin levels were measured by enzyme linked immunoabsorbent assay (ELISA) kit (Millipore, USA) according to the manufacturer’s instruction.

Data preparation and statistical analysis

Data analysis was conducted by Statistical Package for the Social Sciences (SPSS; version 19.0) software. Spearman’s product-moment correlation coefficient was used to explore the relationship between variables. Within a 95% confidence interval, correlation between two groups was accepted as significant if the p value was <0.05.
Results

The prospective study included 81 patients with PCOS. Anthropometric, hormonal and biochemical parameters and serum adiponectin value of patients with PCOS are shown in table 1.

Relationship between serum adiponectin level with clinic, metabolic and biochemical parameters are shown in table 2.

Significant reverse correlation was determined between the following variables: i. serum adiponectin and fasting insulin levels (p=0.04), ii. serum adiponectin and fasting glucose levels (p=0.02), and iii. serum adiponectin levels and HOMA-IR score (p=0.02).

Significant reverse correlation was observed between adiponectin level and degree of insulin resistance in patients with PCOS. There is a significant reverse correlation between serum adiponectin and BMI for patients with PCOS (p=0.001). Significant reverse correlation was observed between adiponectin level and prolactin level (p=0.005), but this situation was not an essential objective of the study; therefore, further studies should be performed to investigate any possible relation between adiponectin and prolactin levels for predicting possible metabolic abnormalities.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Count</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Y)</td>
<td>81</td>
<td>19</td>
<td>13</td>
<td>24</td>
<td>11</td>
</tr>
<tr>
<td>Height (m)</td>
<td>81</td>
<td>1.61</td>
<td>1.45</td>
<td>1.81</td>
<td>0.36</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>81</td>
<td>60</td>
<td>45</td>
<td>96</td>
<td>51</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>81</td>
<td>27.2</td>
<td>23.4</td>
<td>31.0</td>
<td>21</td>
</tr>
<tr>
<td>Free testosterone (pg/ml)</td>
<td>81</td>
<td>2.00</td>
<td>.33</td>
<td>10.14</td>
<td>9.81</td>
</tr>
<tr>
<td>Ferriman-Gallwey</td>
<td>81</td>
<td>6</td>
<td>2</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Fasting glucose (mg/dl)</td>
<td>81</td>
<td>88.80</td>
<td>72.90</td>
<td>135.00</td>
<td>62.10</td>
</tr>
<tr>
<td>Insulin (µIU/ml)</td>
<td>81</td>
<td>9.69</td>
<td>2.00</td>
<td>109.37</td>
<td>107.37</td>
</tr>
<tr>
<td>OGGT 2. hour (mg/dl)</td>
<td>81</td>
<td>100.85</td>
<td>52.30</td>
<td>196.90</td>
<td>144.60</td>
</tr>
<tr>
<td>Prolactin (ng/ml)</td>
<td>81</td>
<td>11.29</td>
<td>4.88</td>
<td>58.10</td>
<td>53.22</td>
</tr>
<tr>
<td>17-OH progesterone (ng/ml)</td>
<td>81</td>
<td>2.00</td>
<td>0.5</td>
<td>6.47</td>
<td>5.97</td>
</tr>
<tr>
<td>HOMA-IR [(uIU/ml x mg/dl)/22, 5]</td>
<td>81</td>
<td>5.54</td>
<td>5.54</td>
<td>5.54</td>
<td>31.46</td>
</tr>
<tr>
<td>Adiponectin (ng/ml)</td>
<td>81</td>
<td>20.90</td>
<td>12.40</td>
<td>40.40</td>
<td>28</td>
</tr>
</tbody>
</table>
Table 2: Relationship between serum adiponectin level and clinic, metabolic, and biochemical parameters

<table>
<thead>
<tr>
<th>Groups</th>
<th>Rho</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Y)</td>
<td>0.127</td>
<td>0.3</td>
</tr>
<tr>
<td>Height (m)</td>
<td>-0.05</td>
<td>0.67</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>-0.137</td>
<td>0.27</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>-0.354</td>
<td>0.001*</td>
</tr>
<tr>
<td>Ferriman-Gallaway</td>
<td>-0.017</td>
<td>0.88</td>
</tr>
<tr>
<td>Prolactin (ng/ml)</td>
<td>-0.339</td>
<td>0.005*</td>
</tr>
<tr>
<td>Insulin (uIU/ml)</td>
<td>-0.228</td>
<td>0.04*</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>-0.25</td>
<td>0.02*</td>
</tr>
<tr>
<td>HOMA-IR [(uIU/ml x mg/dl)/22, 5]</td>
<td>-0.264</td>
<td>0.02*</td>
</tr>
<tr>
<td>OGGT 2. hour (mg/dl)</td>
<td>0.001</td>
<td>0.99</td>
</tr>
<tr>
<td>Free testosterone (pg/ml)</td>
<td>0.173</td>
<td>0.17</td>
</tr>
</tbody>
</table>

Spearman’s correlation coefficient test is used, and values are not normally distributed.

*; The value of p<0.05 is significant.

Discussion

The present study demonstrated that in polycystic ovary syndrome patients, when serum adiponectin level decreased, degree of insulin resistance increased, and that there was also a significant reverse correlation between serum adiponectin and BMI in patients with PCOS.

PCOS includes multiple metabolic abnormalities in addition to polycystic ovaries, so the most important indications in recent studies are insulin resistance and hyperinsulinemia (10, 11). In our study, degree of insulin resistance and pattern were demonstrated in PCOS patients. The correlations between metabolic parameters and serum adiponectin were also investigated, and the result confirms that metabolic parameters are significantly correlated with adiponectin serum level.

The group of mediators synthesized and secreted from adipose tissue are leptin, adiponectin, tumor necrosis factor alpha (TNF-α), ghrelin, retinol-binding protein-4 (RBP-4), resistin, visfatin, and apelin. These molecules are involved in many physiological processes such as lipid metabolism atherosclerosis, blood pressure regulation, insulin sensitivity, and angiogenesis and affect immunity and inflammation.

Adiponectin serum level plays an important role in the development of T2DM due to its unique contribution to increasing insulin sensitivity and to improving islet beta cell dysfunction and fatty acid beta-oxidation (12-14). It is well established that lowered adiponectin concentration is associated with T2DM, obesity, dyslipidemia, insulin resistance and cardiovascular diseases (15-20).

Panidis et al. (21) demonstrated that PCOS patients with higher insulin resistance calculated by HOMA-IR score have lower serum adiponectin levels than the normal population. In our study, we observed similar findings, and also determined a significant correlation between HOMA-IR score and adiponectin serum level.

Xita et al. (22) demonstrated that obese PCOS patients have lower adiponectin serum level than
normal weight PCOS patients. In researches (2, 5, 9) has showed that there is a general correlation between insulin resistance and adiponectin level. We observed the same characteristics in our study.

Free testosterone is the best marker in the definition of hirsutism. In a recent study, no significant relation between serum adiponectin and androgen level was identified in healthy women (23), whereas higher androgen serum level was found with increasing adiponectin serum level in PCOS patients (24, 25); however, in some studies, no relationship was demonstrated between these two parameters (26, 27). According to Nishizawa et al. (28) serum adiponectin level can be reduced by androgen therapy; in addition, there is evidence that supplementation of flutamide and metformine plus oral contraceptive therapy reduce adiponectin serum level in adolescents with hirsutism (29). In our study, no significant correlation was observed between serum adiponectin and free testosterone levels.

Since we did not encounter any study about correlation between adiponectin and prolactin in literature research, we tried to investigate any correlation between these serum markers in PCOS patients. de Assunção Alves Rodrigues LF et al. (30) have showed that prolactinoma is associated with hypoadiponectinemia. In this study, adiponectin level was compared between patients with prolactinoma and controls, and the result demonstrated that patients with prolactinomas showed higher insulin level and HOMA-IR score with lower adiponectin level (29). Although the role of prolactin on glucose metabolism is still unclear, it has been demonstrated high prolactin level improves β-cell mass by increasing β-cell proliferation and exacerbates insulin resistance (30). But, in our study, patients whose serum prolactin levels were outside the normal range were excluded. Serum adiponectin level was determined to have significantly reverse correlation with prolactin level within the normal range. This finding shows prolactine has a role in insulin resistance. Therefore, we consider serum level of prolactin as directive marker for metabolic abnormalities in PCOS patient.

The patients with heterogenous distribution of BMI may be an acceptable argumentative term of our study. Although all PCOS patients were considered according to current diagnosis criteria, patients with standardized BMI value were unavailable in our study.

**Conclusion**

Although the exact pathogenesis of PCOS is obscure, it is generally accepted that insulin resistance, hyperinsulinemia and clinical and/or biochemical hyperandrogenism may play a role in its pathogenesis. The most implicated factor in our study was insulin resistance, which is consistent with the mentioned-literatures. There was also a correlation between adiponectin level and the degree of insulin resistance. An investigation of the degree of insulin resistance may help physicians to predict further systemic morbidity of PCOS. We consider serum adiponectin level as an adequate serum marker for demonstrating the degree and pattern of insulin resistance in PCOS patients.

**Acknowledgements**

All authors contributing in article are available in the paper authors list. No company or organization supported our study, financially. There is no conflict of interest in this article.

**References**


